期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 104, 期 2, 页码 356-363出版社
WILEY
DOI: 10.1002/cpt.934
关键词
-
资金
- National Institute on Drug Abuse of the National Institutes of Health [R44DA041815]
- National Heart, Lung, and Blood Institute of the National Institutes of Health [R43HL110739]
US Food and Drug Administration (FDA) investigators recently demonstrated in a crossover study that early (J-T(peak)c) and late (T-peak-T-end) repolarization duration can differentiate selective potassium block with a high arrhythmia risk from multichannel block with lower risk in subjects receiving dofetilide, verapamil, quinidine, or ranolazine. The purpose of this study was to determine if the findings by the FDA using their published software algorithm could be corroborated using an alternative software algorithm for the same metrics and to determine if methodological differences resulted in clinically meaningful differences in interpretation. Exposure-response relationships computed with linear mixed effects models and mean maximal effects on ECG intervals measured by the two algorithms were similar, corroborating the FDA findings, but with some differences in the modeled slopes and magnitude of changes. The alternative software resulted in an average 25% reduction in the 95% confidence intervals of the mixed effects models with generally lower Akaike Information Criterion values.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据